Physician profile
Dwight Thibodeaux
NPI 1962516039
$5,314.60
in general payments reported to CMS, 2019-2025
21 companies · $1,019 in 2025
The $1,019 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $324 · 2021: $630 · 2022: $1,257 · 2023: $741 · 2024: $685 · 2025: $1,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,445.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,102.28 | 2022-2025 | Infuse, Xiidra, Miebo |
| Abbvie INC. | $632.14 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Dompe US, INC. | $529.35 | 2022-2025 | Oxervate |
| Allergan, INC. | $446.24 | 2019-2022 | |
| Alcon Vision LLC | $425.84 | 2019-2025 | Precision7, Eysuvis, Total30 |
| Sight Sciences, INC. | $357.51 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $351.77 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $293.67 | 2020-2025 | Cequa |
| Aerie Pharmaceuticals, INC. | $231.13 | 2019 | |
| Shire North American Group INC | $140.26 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $121.37 | 2025 | Xdemvy |
| Coopervision INC. | $109.30 | 2022-2025 | Myday Contact Lens |
| Apellis Pharmaceuticals, INC. | $108.75 | 2023 | Syfovre |
| Mallinckrodt Hospital Products INC. | $94.61 | 2020-2021 | |
| Johnson & Johnson Vision Care, INC. | $93.34 | 2019-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abb Con-Cise Optical Group LLC | $79.56 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $66.94 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $42.58 | 2021-2022 | |
| Biotissue Holdings INC. | $40.19 | 2022-2023 | |
| Harrow Eye, LLC | $28.37 | 2025 | Vevye |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dwight Thibodeaux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.